Publications by authors named "P M LoRusso"
Purpose: Financial toxicity (FT) adversely influences patient quality of life and is a barrier to clinical trial enrollment. Early-phase clinical trials (EPCTs) recruit patients who may have high baseline FT and require additional visits and procedures, potentially increasing FT.
Methods: In this prospective survey study, we sought to assess FT at baseline and after 2 months among patients with advanced solid malignancies participating in EPCTs.
Ochratoxin A (OTA) is a mycotoxin produced by fungi species belonging to the genera spp. and spp. The proliferation of OTA-producing fungal species may occur due to inadequate practices during both the pre-harvest and post-harvest stages of feed.
View Article and Find Full Text PDFArticle Synopsis
- Transforming growth factor (TGF)-ß1 is known to encourage tumor growth while also suppressing the immune system's ability to fight tumors; its latent form is associated with glycoprotein-A repetition predominant (GARP) on regulatory T cells.
- Livmoniplimab is a monoclonal antibody that targets the GARP:TGF-ß1 complex to impede the activation and release of TGF-ß1, and it's being studied in combination with another antibody, budigalimab, in a clinical trial for patients with advanced solid tumors.
- In the trial, 57 patients were treated with dosages ranging up to 1500mg, with manageable side effects like fatigue and nausea reported; while no
Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs.
View Article and Find Full Text PDFPurpose: To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS G12C mutation treated with single-agent divarasib (GDC-6036) in a phase 1 study.
Experimental Design: Plasma samples were collected for serial ctDNA profiling at baseline (cycle 1 day 1 prior to treatment) and multiple on-treatment time points (cycle 1 day 15 and cycle 3 day 1).
Results: KRAS G12C ctDNA was detectable from plasma samples in 72.